Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.
Joleen M. Hubbard(Rutgers, The State University of New Jersey), Axel Grothey(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Daniel H. Ahn(Mayo Clinic Hospital), Tanios Bekaii‐Saab(WinnMed), Nathan R. Foster(University Health Network), Nitin Mishra(Mayo Clinic), Alexis D. Leal(Mayo Clinic in Arizona)
Cited by 1
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
|JNCI Journal of the National Cancer Institute|2011|527